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Abstract  
No study has evaluated the incidence of new cases of thyroid autoimmunity (AT) and 
dysfunction (TD) in hepatitis C-associated mixed cryoglobulinemia (MC) patients. 
We aimed to evaluate the incidence of new cases of AT and TD in a wide group of 
MC patients, vs. age- and gender-matched controls from the same geographic area. 
After exclusion of MC patients with TD at the initial evaluation, the appearance of 
new cases of TD was evaluated in 112 MC patients and 112 matched controls, with 
similar iodine intake (median follow-up 67 months in MC vs. 78 in controls). 
A high incidence (P<0.05) of new cases of hypothyroidism, TD, anti-thyroperoxidase 
antibody (AbTPO) positivity, appearance of a hypoechoic thyroid pattern, and thyroid 
autoimmunity in MC patients vs. controls was shown. A logistic regression analysis 
showed that in MC the appearance of hypothyroidism was related to female gender, a 
border line high initial thyroid-stimulating hormone (TSH), AbTPO positivity, a 
hypoechoic and small thyroid. 
In conclusion, we show a high incidence of new cases of AT and TD in MC patients. 
MC patients at high risk (female gender, a border line high initial TSH, AbTPO 
positivity, a hypoechoic and small thyroid) should have periodically thyroid function 
follow-up. 
 
Key terms: hepatitis C-associated mixed cryoglobulinemia, autoimmune thyroiditis, 
thyroid autoimmunity, hypothyroidism, anti-thyroid-peroxidase antibody, TSH. 
 
 
 
 
 
 
 
 
Take-home messages:  
 
• The most important systemic HCV-related extrahepatic disease (HCV-EHD) is 
HCV-related mixed cryoglobulinemia (MC+HCV) and the most frequent and 
clinically important endocrine HCV-EHDs are thyroid disorders.  
• Increased circulating levels of AbTPO, and increased risk of hypothyroidism in 
female gender and AbTPO positive subjects characterized the pattern of thyroid 
disorders observed in MC+HCV patients. 
• To the best of our knowledge, no study has evaluated the incidence of thyroid 
disorders in cryoglobulinemia.  
• In this paper we show an elevated incidence of new cases of hypothyroidism, 
thyroid dysfunction, AbTPO positivity, appearance of a hypoechoic thyroid pattern 
and thyroid auoimmunity in MC+HCV patients with respect to controls. 
• As shown by a logistic regression analysis, in MC+HCV patients the appearance of 
hypothyroidism was related to female gender, a TSH value at a border line high level 
(though in the normal range), the presence of AbTPO positivity, and a small thyroid 
volume, according with what reported by other studies in the general population.  
• The clinical profile in MC+HCV patients should involve thyroid function 
evaluation and ultrasonography, and in the ones at high risk [female gender with a 
border line high (though in the normal range) TSH, positive AbTPO, hypoechoic and 
small thyroid] thyroid function follow-up and appropriate treatments should be 
evaluated periodically (approximately every year).
 1. Introduction 
The most important systemic hepatitis C virus (HCV)-related extrahepatic disease 
(HCV-EHD) is HCV-related mixed cryoglobulinemia (MC+HCV) and the most 
frequent and clinically important endocrine HCV-EHDs are thyroid disorders.  
Many studies have been addressed to evaluate the prevalence of thyroid autoimmunity 
(AT) in HCV infected patients, reporting conflicting results.  
A large study investigated the prevalence of thyroid disorders in 630 consecutive 
patients with HCV chronic hepatitis (CHC) with respect to: a control group from an 
iodine-deficient area (389 subjects); another control group living in an area of iodine 
sufficiency (268 persons); 86 patients with chronic hepatitis B virus (HBV) infection. 
Patients with CHC had more frequently hypothyroidism (13%), anti–thyroperoxidase 
antibodies (AbTPO) (21%), or anti–thyroglobulin antibodies (AbTg) (17%), than the 
control groups [1, 2]. Also a meta-analysis of the literature reported a significant 
association between CHC and AT [3-5]. Furthermore, more recently a retrospective 
cohort study of users of US Veterans Affairs health care facilities, which included 
146,394 CHC patients, and 572,293 controls, confirmed the thyroiditis risk was 
significantly increased in CHC patients [6]. 
Some studies evaluated autoimmune thyroid disorders (AITD) in MC+HCV patients. 
Codes et al. [7] studied 127 CHC patients. In CHC patients infected by genotype 3 (P 
= 0.05) thyroid dysfunction (TD) occurred in 23.3% and cryoglobulinemia in 38%. 
Zarebska-Michaluk et al. [8] studied 340 untreated CHC consecutive patients. Two 
hundred ten patients with CHC (61.7%) presented at least 1 HCV-EHDs, including 
MC (37.1%), and AT (16.2%). Furthermore, anecdotal studies reported TD in 
MC+HCV patients [9, 10].  
More recently, a case-control prospective study has been conducted in 93 MC+HCV 
patients, matched by gender and age (+/- 2 years) to 93 CHC patients without MC and 
93 HCV-negative controls. Thyroid autoimmune manifestations [AbTPO (28% vs. 
9%), serum AbTPO and/or AbTg (31% vs. 12%), AT (35% vs. 16%)], and  
subclinical hypothyroidism (11% vs. 2%), were more frequent in MC+HCV patients 
than in HCV-negative controls, or in CHC patients (AbTPO, 28% vs. 14%) [11]. 
Increased circulating levels of AbTPO, and increased risk of hypothyroidism in 
female gender and AbTPO positive subjects characterized the pattern of thyroid 
disorders observed in MC+HCV patients [2, 4]. 
To the best of our knowledge, no study has evaluated the incidence of thyroid 
disorders in cryoglobulinemia.  
The aim of our study was to evaluate the incidence of new cases of clinical and 
subclinical TD in a wide group of MC+HCV patients. 
 
2. Patients and Methods 
One hundred and fifty-one MC+HCV patients consecutively referred to the Internal 
Medicine or Rheumatology Units of the University of Pisa and Modena (from 1992 to 
2011) underwent a thyroid evaluation.  
The diagnosis of MC was based on the presence of serum mixed (IgG-IgM) 
cryoglobulins and the classical clinical triad (purpura, weakness, arthralgias), and the 
exclusion of other well-known systemic disorders, such as immuno-rheumatic, 
neoplastic, and infectious diseases [12, 13].  
HCV infection was systematically evaluated in all patients, who were excluded if they 
were HCV-negative.   
MC+HCV patients were excluded from the study, if they had been previously treated 
with external radiotherapy in the region of the neck or mediastinum, or if they had had 
IFNalpha treatments. 
Among the MC+HCV patients, those with subclinical or clinical hypothyroidism, 
subclinical hyperthyroidism or Graves’ disesase, were excluded too. One hundred 
twelve MC+HCV patients without TD were eligible for the longitudinal study. They 
were studied again, at least 1 year after the initial evaluation, one or more times. The 
median follow-up period from the initial evaluation was 67 months (range 12-191 
months).  
Each of the 112 MC+HCV patients eligible for the study was gender- and age-
matched, one-to-one with a control group, without TD, of the background population 
from the same geographic area (North-West Tuscany) with a similar iodine intake 
(that is an important environmental risk factor for the appearance of thyroid 
autoimmune disorders) [14].  
This control group was extracted from a larger sample of > 2000 subjects in a 
population-based survey of thyroid disorders, who were initially studied in 1994 and 
subsequently reevaluated (by thyroid function, autoantibodies and ultrasonography) in 
2002-2003 (see above). The median follow-up period from the initial evaluation was 
97 months (range 87-112 months).  
All 112 MC+HCV patients and controls were reevaluated, by: a- physical 
examination; b- thyroid ultrasonography, as previously reported [15]; c- circulating 
free triiodothyronine (FT3) and free thyroxine (FT4) (AMERLEX-MAB FT3/FT4 
Kit; Amersham, UK), thyroid-stimulating hormone (TSH) (reference range 0.3-3.6 
µU/mL) (DiaSorin, USA), AbTPO and AbTg antibodies (ICN Pharmaceuticals, USA; 
positivity > 100 IU/mL).  
If TD appeared during the follow-up, 112 MC+HCV patients were appropriately 
treated and excluded from a further evaluation. 
The study was approved by the institutional ethic committee, and all subjects gave 
their informed written consent to participate.  
Mean group values were compared using one-way ANOVA for normally distributed 
variables, otherwise by the Mann-Whitney U test. The χ2 test was used to compare 
categorical variables. A logistic regression analysis was performed in MC+HCV 
patients including gender, age, smoking, TSH, AbTPO positivity, AbTg positivity, 
thyroid hypoechogenicity (presence/absence), thyroid volume (all at the start of 
evaluation) as independent variables, and hypothyroidism at last evaluation as 
dependent variable.  
 
3. Results 
The clinical features of the 112 eligible MC+HCV patients are reported in Table 1.  
The thyroid status of MC+HCV patients entering the longitudinal study and matched 
controls is reported in Table 2. The prevalence of subjects with positive AbTPO, 
thyroid hypoechoic pattern, and thyroid volume < 6 mL were higher in the MC+HCV 
group than in controls (Table 2), and TSH was slightly but significantly higher in 
MC+HCV patients. On the whole, indices of thyroid autoimmunity (AbTg, or 
AbTPO, or ultrasonographic diagnosis of thyroiditis) were more frequent in 
MC+HCV than in controls.  
At the last evaluation (after a median of 67 and 97 months, respectively in MC+HCV 
patients and controls: P < 0.01, ANOVA) TSH levels and AbTPO titers were 
significantly higher in MC+HCV patients than in controls (Table 2). Subclinical 
hypothyroidism was more common in MC+HCV patients than in controls. The 
prevalence of subclinical hyperthyroidism was higher in MC+HCV patients than in 
controls. On the whole the prevalence of TD (subclinical or clinical hypo- and hyper-
thyroidism) was significantly more frequent in MC+HCV patients (Table 2). The 
prevalence of subjects with positive AbTPO, thyroid hypoechoic pattern, and thyroid 
volume < 6 mL was significantly higher in the MC+HCV group than in controls.  
The prevalence and the incidence of new cases of thyroid disorders is reported in 
Table 3. Thyroid dysfunctions, subclinical hypothyroidism, hypothyroidism, AbTPO 
positivity, a thyroid hypoechoic pattern, and thyroid autoimmunity were significantly 
more frequent in MC+HCV than in controls.  
The possible association of thyroid disorders with clinical and serological parameters 
of MC+HCV patients was investigated in the patients with TD, however no statistical 
significant difference was observed with respect to MC+HCV patients without TD. 
In MC+HCV patients at the end of the follow-up, hypothyroidism was significantly 
associated with presence of AbTPO-positivity (P < 0.001), a small thyroid volume (< 
6 mL) (P < 0.01), and a hypoechoic pattern (P < 0.01) (all by χ2); no relationship was 
found with the other thyroid parameters. Moreover, no significant association was 
observed among the clinical and serological parameters of MC+HCV patients and 
thyroid autoantibodies, or others of the studied parameters.  
In MC+HCV patients, the logistic regression analysis [in a model including, age, 
gender, TSH value, AbTPO positivity, AbTg positivity, thyroid hypoechogenicity 
(presence/absence), thyroid volume (all at the start of evaluation) as independent 
variables, and hypothyroidism at last evaluation as dependent variable] shows that the 
appearance of hypothyroidism was related to, female gender [coefficient, 0.872; 
Exp(coef), 2.378; 95% lower, 1.231; 95% upper, 5.67; P = 0.001],  a border line 
high initial TSH [coefficient, 0.931; Exp(coef), 2.104; 95% lower, 1.014; 95% upper, 
4.51; P = 0.045], AbTPO positivity [coefficient, 0.801; Exp(coef), 1.973; 95% lower, 
1.101; 95% upper, 3.562; P = 0.0178], and a small thyroid volume [coefficient, -
0.211; Exp(coef), 0.821; 95% lower, 0.794; 95% upper, 0.923; P < 0.01]. 
 
4. Discussion 	  
In this paper we show an elevated incidence of new cases of hypothyroidism, TD, 
AbTPO positivity, appearance of a hypoechoic thyroid pattern, and thyroid 
autoimmunity in MC+HCV patients with respect to controls. It is noteworthy that the 
incidence of new cases of hypothyroidism and AbTPO in control subjects was similar 
to the one reported by other epidemiological studies [16-18], indicating that the 
control group is not biased, vs. a low AT [19].  
Mean TSH value, thyroid hypoechoic pattern and small thyroid volume, and the 
percentage of antithyroid antibodies were significantly higher in MC+HCV patients 
than in the control group, according with other studies, and our previous transversal 
study [20]. 
As shown by the logistic regression analysis, in MC+HCV patients the appearance of 
hypothyroidism was related to female gender, a TSH value at a border line high level 
(though in the normal range), the presence of AbTPO positivity, and a small thyroid 
volume, according with what reported by other studies in the general population [16-
18].  
The significant differences between MC+HCV patients and controls, in the baseline 
thyroid parameters, may account for the higher incidence of hypothyroidism in the 
MC+HCV group, at least in part. 
The association of autoimmune disorders is well known [21], even if its pathogenetic 
base is still under investigation [22, 23]. 
A predominant Th1 immune pattern has been shown in target organs of patients with 
chronic AT, or Graves' ophthalmopathy, or type 1 diabetes, at the beginning of these 
diseases, as demonstrated by data reported from animal models and available in 
humans [24-26]. In the initial and active phase of MC+HCV, too, a prevalent Th1 
immune reactivity is evident, that switches to a predominant Th2 immune response in 
the inactive phase [27, 28]. Such prevalence of the Th1 immune reactivity at the 
beginning of both MC+HCV, and AT, under the influence of genetic and 
environmental conditions, could cause the appearance of autoimmune phenomena 
involving different organs in the same subject [29, 30].  
In conclusion, we demonstrate a high incidence of new cases of hypothyroidism, TD, 
AbTPO positivity, appearance of a small thyroid and a hypoechoic thyroid pattern in 
MC+HCV patients, overall in female gender with respect to control subjects. A TSH 
value at a border line high level (though in the normal range), the presence of AbTPO 
positivity, and a small thyroid volume, in female gender, are risk factors for the 
development of TD. The clinical profile in MC+HCV patients should involve thyroid 
function evaluation and ultrasonography. In female patients at high risk [a border line 
high (though in the normal range) TSH, positive AbTPO, hypoechoic and small 
thyroid] thyroid function follow-up and appropriate treatments should be evaluated 
periodically (approximately every year). 
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 Table 1. Demographic and clinico-serological features of 112 MC+HCV patients. 
 
Age (years) 
 
62 ± 15  
Men/Women 26/86 
Disease duration with MC (years) 14 ± 10   
Purpura 86% 
Active vasculitis 41% 
Weakness 99% 
Arthralgias 92% 
Arthritis 15% 
Raynaud's phenomenon 47% 
Sjogren's syndrome 44% 
Peripheral neuropathy 77% 
Renal involvement* 11% 
Aminotransferases elevation and/or histologic activity† 85% 
Cryocrit (%)   4.6 ± 9.2       
CH50 (normal: 160-220 units) 114 ± 45    
C3 (normal: 60-130 mg/dl) 79 ± 44   
C4 (normal 20-55 mg/dl) 12 ± 7       
Autoantibodies ‡ 34% 
 
* Serum creatinine >1.5 mg/dl and/or proteinuria >0.5 gr/24h. 
† Increase of the liver enzyme (alanine aminotransferase) and/or histological 
alterations. 
‡ Presence of anti-nuclear and/or anti-mitochondrial and /or anti-smooth muscle 
and/or anti-extractable nuclear antigen autoantibodies. 
 Table 2.	  Comparison of thyroid status at the initial, or at the last evaluation, between 
MC+HCV patients and matched controls.	  
 Initial thyroid status  Last evaluation 
 MC+HCV Controls P  MC+HCV Controls P 
N° 112 112   112 112  
Age, y (SD) 62 ± 15 61 ± 17 ns  68 ± 14 68 ± 16 ns 
Gender (Men/Women)  26/86 26/86 ns  26/86 26/86 ns 
TSH, µU/mL (SD) 2.0 (0.6)b 1.2 (0.7) 0.037a  2.8 (3.9)b 1.4 (1.0) 0.012a 
FT4, pmol/L (SD) 110 (5.0) 121 (3.3) ns  108 (5.4) 120 (3.6) ns 
FT3, pmol/L (SD) 4.3 (1.9) 4.9 (1.2) ns  4.2 (2.0) 4.8 (1.1) ns 
AbTg, IU/mL (SD) 101 (163) 19 (65) 0.034  132 (271) 28 (87) 0.022 
AbTPO, IU/mL (SD) 87 (203)b 17 (32) 0.019a  154 (311)b 31 (61) 0.011a 
Subclinical hypothyroidism 0% 0% ns  (9)9.8% (2)1.8% 0.101c 
Clinical hypothyroidism 0% 0% ns  (2)1.8% (1)0.8% ns 
Subclinical hyperthyroidism 0% 0% ns  (8)7.1% (3)2.6% ns 
Graves’ disease 0% 0% ns  0% 0% ns 
Thyroid dysfunctions 0% 0% ns  (19)17% (5)4.5% 0.002c 
AbTg+ (10)8.9% (5)4.5% ns  (14)12.5% (7)6.2% ns 
AbTPO+ (21)18.7% (11)9.8% 0.056c  32(28.6%) (13)11.6% 0.001c 
Hypoechoic pattern (23)20.5% (14)12.5% 0.105c  (35)31.2% (17)15.1% <0.004c 
Thyroid autoimmunity (23)20.5% (15)13.3% 0.154c  (37)33% (18)16.1%  <0.032c 
Thyroid volume, mL (SD) 12 (11) 13(14) ns  10 (12) 13 (12) ns 
Thyroid volume > 20 mL  10% 12% ns  9% 12% ns 
Thyroid volume < 6 mL (10)8.9% (4)3.6% 0.097c  (19)17%  (5)4.4% 0.001c 
TSH = thyroid stimulating hormone; AbTPO = anti-thyroperoxidase antibody; AbTPO+ = anti-thyroperoxidase 
antibodies >100 IU/ml; AbTg = anti-thyroglobulin antibody; AbTg+ = anti-thyroglobulin antibodies >100 
IU/ml; FT3 = free triiodothyronine; FT4 = free thyroxine; AbTg+ or AbTPO+ or ultrasonographic diagnosis of 
thyroiditis = thyroid autoimmunity. a = ANOVA. b = TSH levels and AbTPO titers were significantly higher in 
MC+HCV than in controls. c = χ2.  
 
 
 Table 3. New cases and incidence c of thyroid disorders in MC+HCV patients at the 
last evaluation. 
 
 
MC+HCV patients 
number new cases 
(incidence) 
Controls 
number new cases 
(incidence) 
Pb 
 
Subclinical hypothyroidism 9 (14.4 c) 2 (2.7 c) 0.030 
Clinical hypothyroidism 2 (3.2 c) 1 (1.4 c) ns 
Hypothyroidism 11 (17.5 c) 3 (4.1 c) 0.027 
Subclinical  hyperthyroidism 8 (12.8 c) 3 (4.1 c) 0.122 
Graves’ disease 0 (0) 0 (0)    ns 
Hyperthyroidism 8 (12.8 c) 3 (4.1 c) ns 
Thyroid dysfunction 19 (30.3 c) 6 (8.2 c) 0.005 
AbTg+ 5 (8 c) 2 (2.7 c) ns 
AbTPO+ 11 (17.5 c) 2 (2.7 c) 0.010 
Hypoechoic pattern 12 (19.1 c) 3 (4.1 c) 0.011 
Thyroid autoimmunity 14 (22.3 c) 3 (4.1 c) 0.055 
Thyroid volume > 20 mL 0 (0) 1 (1.4 c) ns 
Thyroid volume < 6 mL 9 (14.4 c) 1 (1.4 c) 0.009 
a Incidence is reported in parenthesis. Incidence = [incidence = number of new cases / 
patients (112) x years of follow-up (67 months = 5.6 years) = number of new events / 627 
patients per year)] and matched controls [incidence = number of new cases / subjects (112) x 
years of follow-up (78 months = 6.5 years) = number of new events / 728 patients per year)].  
b = χ2 (number of new cases).  
c = with respect to 1000 patients with MC+HCV per year. 
AbTPO = anti-thyroperoxidase antibody; AbTPO+ = anti-thyroperoxidase antibodies >100 
IU/mL; AbTg = anti-thyroglobulin antibody; AbTg+ = anti-thyroglobulin antibodies >100 
IU/mL. 
 
 
